Milford manufacturing facility part of $32B sale
Photo Courtesy Milford Assesor's Office
Baxalta's Milford manufacturing facility could be relocated following the company's acquisition by Shire PLC.
The status of Baxalta’s Milford manufacturing facility is up in the air following the acquisition of the Illinois company by Shire PLC.
The $32 billion agreement between the two companies was finalized Monday, and will probably close mid-way through 2016, according to Shire officials. The deal has the potential to create the largest provider for therapies of rare diseases with the combined biotechnology company projected to deliver over $20 billion in annual revenues by 2020.
What is unclear is what will happen to Baxalta's approximately 16,000 employees worldwide, including employees in Cambridge and at the manufacturing plant in Milford that makes a treatment for hemophilia.
No decisions have been made regarding merging the work forces of the two companies, according to Shire spokesperson Michele Galen.
The 43,000 square foot Milford facility is located at 27 Maple St. and employed just under 80 employees when it was sold in 2013 to Baxter International, Inc., which has since been renamed to Baxalta.
WBJ Web Partners
Most Recent
Most Recent
0 Comments